What is William Blair’s Estimate for TMO FY2025 Earnings?

Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities researchers at William Blair raised their FY2025 earnings per share estimates for Thermo Fisher Scientific in a report issued on Wednesday, October 22nd. William Blair analyst M. Larew now anticipates that the medical research company will post earnings of $22.76 per share for the year, up from their prior estimate of $22.44. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. William Blair also issued estimates for Thermo Fisher Scientific’s Q4 2025 earnings at $6.47 EPS, Q1 2026 earnings at $5.84 EPS, Q2 2026 earnings at $5.93 EPS, Q3 2026 earnings at $6.21 EPS, Q4 2026 earnings at $6.91 EPS and FY2026 earnings at $24.90 EPS.

A number of other equities research analysts also recently commented on TMO. Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Citigroup raised their price target on Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a report on Thursday. Leerink Partners upped their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday. TD Cowen raised their target price on Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a report on Thursday. Finally, Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Nineteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $595.75.

Thermo Fisher Scientific Stock Up 0.8%

Shares of NYSE:TMO opened at $571.94 on Friday. Thermo Fisher Scientific has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The firm’s 50-day simple moving average is $502.38 and its 200-day simple moving average is $452.23. The company has a market cap of $215.97 billion, a price-to-earnings ratio of 33.04, a PEG ratio of 3.25 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period last year, the company earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Thermo Fisher Scientific by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company’s stock valued at $13,700,154,000 after purchasing an additional 309,207 shares during the last quarter. Norges Bank acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $2,264,615,000. Franklin Resources Inc. boosted its position in Thermo Fisher Scientific by 11.3% during the second quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company’s stock worth $1,985,759,000 after acquiring an additional 498,238 shares during the last quarter. Amundi grew its stake in Thermo Fisher Scientific by 5.9% in the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock worth $1,426,316,000 after acquiring an additional 168,197 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Thermo Fisher Scientific by 2.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 3,000,562 shares of the medical research company’s stock valued at $1,216,612,000 after acquiring an additional 74,971 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the transaction, the chief executive officer owned 113,762 shares of the company’s stock, valued at $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,666 shares of company stock worth $13,990,971 over the last quarter. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.